<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03925896</url>
  </required_header>
  <id_info>
    <org_study_id>B2019-021</org_study_id>
    <nct_id>NCT03925896</nct_id>
  </id_info>
  <brief_title>Phase I Trial of LMP2 Antigen-specific TCR T-cell Therapy for Recurrent and Metastatic NPC Patients</brief_title>
  <official_title>LMP2 Antigen-specific High-affinity T Cell Receptor (TCR)-Transduced Autologous T-cell Therapy for Recurrent and Metastatic Nasopharyngeal Carcinoma, an Open-label, Single-center, Phase I Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sun Yat-sen University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sun Yat-sen University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      In this study, a single-arm, open-labeled clinical trial will be performed to determine the
      safety and efficacy of EBV TCR-T cells in the treatment of recurrent/metastatic
      nasopharyngeal carcinoma with positive EBV infection in the Chinese population.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      All enrolled subjects will be infused with EBV TCR-T cells. The project which enrolls 27
      patients, according to the patient's HLA subtypes will be divided into HLA-A2, HLA-A11,
      HLA-A24 three groups, 9 patients in each group. Using a dose climbing method, each group will
      be divided into three dose subgroups. In the first dose subgroup, 5×106/kg TCR-T cells will
      be returned, and in the second dose subgroup, 1×107/kg TCR-T cells will be returned. The
      third dose subgroup 5 x 107/kg TCR-T cells will be returned.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 7, 2019</start_date>
  <completion_date type="Anticipated">August 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">August 1, 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To Determine the Maximum Tolerated Dose of TCR T-cell Therapy</measure>
    <time_frame>2 years</time_frame>
    <description>Verify the MTD of LMP2 Antigen-specific TCR T-cell Therapy</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">27</enrollment>
  <condition>Nasopharyngeal Carcinoma</condition>
  <arm_group>
    <arm_group_label>LMP2 Antigen-specific TCR T cells</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All enrolled subjects will be infused with EBV TCR-T cells. The project which enrolls 27 patients, according to the patient's HLA subtypes will be divided into HLA-A2, HLA-A11, HLA-A24 three groups, 9 patients in each group. Using a dose climbing method, each group will be divided into three dose subgroups. In the first dose subgroup, 5×106/kg TCR-T cells will be returned, and in the second dose subgroup, 1×107/kg TCR-T cells will be returned. The third dose subgroup 5 x 107/kg TCR-T cells will be returned.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LMP2 Antigen-specific TCR T cells</intervention_name>
    <description>All enrolled subjects will be infused with EBV TCR-T cells. The project which enrolls 27 patients, according to the patient's HLA subtypes will be divided into HLA-A2, HLA-A11, HLA-A24 three groups, 9 patients in each group. Using a dose climbing method, each group will be divided into three dose subgroups. In the first dose subgroup, 5×106/kg TCR-T cells will be returned, and in the second dose subgroup, 1×107/kg TCR-T cells will be returned. The third dose subgroup 5 x 107/kg TCR-T cells will be returned.</description>
    <arm_group_label>LMP2 Antigen-specific TCR T cells</arm_group_label>
    <other_name>EBV specific TCR-T cells</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        1. Patients with nasopharyngeal carcinoma diagnosed by pathology and EBV infection (EBERs
        positive ) ; 2.18-70 years old; 3.MHC-I is HLA-A2, HLA-A11 or HLA-A24 subtype; 4.
        Progression after second-line platinum-containing chemotherapy regimen,
        recurrent/metastatic nasopharyngeal carcinoma patients who are inoperable and non-radiable;
        5. Based on the Response Evaluation Criteria in Solid Tumors version (RECIST 1.1), there
        are ≥ 1 measurable target lesions; 6. Expected survival time is more than 12 weeks; 7. ECOG
        score 0-2 points; 8. Patients with good bone marrow, kidney, liver, and heart, and lung
        function 9. Can establish the venous access required for the collection, no
        contraindications for white blood cell collection; 10. Male and female patients of the
        appropriate age must adopt a reliable method of contraception; 11. Those who understand the
        trial and have signed an informed consent form.

        Exclusion Criteria:

          1. Patients with symptomatic brain metastasis;

          2. Other malignant tumors other than nasopharyngeal carcinoma within 5 years prior to
             enrollment, in addition to appropriate treatment of cervical carcinoma in situ,
             cutaneous basal or squamous cell carcinoma, localized prostate cancer or ductal
             carcinoma in situ after radical surgery ;

          3. Hepatitis B or hepatitis C active period, HIV-infected;

          4. Any other uncontrolled active disease that impedes participation in the trial;

          5. Patients with severe heart and cerebrovascular diseases such as coronary heart
             disease, angina pectoris, myocardial infarction, arrhythmia, cerebral thrombosis, and
             cerebral hemorrhage;

          6. 2-3 grade hypertension or patients with poorly controlled hypertension;

          7. Those with a history of mental illness that are difficult to control;

          8. The investigator believes that it is not appropriate to participate in the trial;

          9. Those who have been using immunosuppressive agents for a long time after organ
             transplantation, except for recent or current inhaled corticosteroids;

         10. In the opinion of the investigator, the presence of medical history or mental state
             history or laboratory abnormalities may increase the risk associated with
             participating in the study or study drug administration, or may interfere with the
             interpretation of the results;

         11. Screening indicates that the target cell transfection rate is less than 30%, or the T
             cell expansion is insufficient (less than 5 times) under CD3/CD28 stimulation
             conditions;

         12. Unstable pulmonary embolism, deep vein thrombosis, or other major arterial/venous
             thromboembolic events occurred 30 days or 30 days prior to grouping. If receiving
             anticoagulant therapy, the subject's therapeutic dose must be stable before grouping;

         13. A subject who is pregnant or breastfeeding, or who is planning a pregnancy during or
             after 2 months of treatment;

         14. Subjects who are women of childbearing age who are reluctant to receive
             high-efficiency contraception (according to institutional standards) during treatment
             and at least 2 months after the end of treatment. Female subjects of childbearing age
             are required to provide a negative result of a serum or urine pregnancy test within 48
             hours prior to treatment;

         15. There are active or uncontrollable infections requiring systemic treatment within 14
             or 14 days prior to grouping;

         16. Subjects who are unwilling or unable to comply with the research requirements.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hai Qiang Mai, MD,PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Sun Yat-sen University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Hai Qiang Mai, MD.PHD</last_name>
    <phone>020-87343380</phone>
    <email>maihq@sysucc.org.cn</email>
  </overall_contact>
  <location>
    <facility>
      <name>Sun Yat-sen Universitty Cancer Center</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510060</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hai-Qiang Mai, MD,PhD</last_name>
      <phone>+862087343643</phone>
      <email>maihq@sysucc.org.cn</email>
    </contact>
    <investigator>
      <last_name>Hai-Qiang Mai, MD,PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <reference>
    <citation>Liao WH, Yang LF, Liu XY, Zhou GF, Jiang WZ, Hou BL, Sun LQ, Cao Y, Wang XY. DCE-MRI assessment of the effect of Epstein-Barr virus-encoded latent membrane protein-1 targeted DNAzyme on tumor vasculature in patients with nasopharyngeal carcinomas. BMC Cancer. 2014 Nov 18;14:835. doi: 10.1186/1471-2407-14-835.</citation>
    <PMID>25407966</PMID>
  </reference>
  <reference>
    <citation>Rosenberg SA, Packard BS, Aebersold PM, Solomon D, Topalian SL, Toy ST, Simon P, Lotze MT, Yang JC, Seipp CA, et al. Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. A preliminary report. N Engl J Med. 1988 Dec 22;319(25):1676-80.</citation>
    <PMID>3264384</PMID>
  </reference>
  <reference>
    <citation>Huang J, Fogg M, Wirth LJ, Daley H, Ritz J, Posner MR, Wang FC, Lorch JH. Epstein-Barr virus-specific adoptive immunotherapy for recurrent, metastatic nasopharyngeal carcinoma. Cancer. 2017 Jul 15;123(14):2642-2650. doi: 10.1002/cncr.30541. Epub 2017 Feb 21.</citation>
    <PMID>28222215</PMID>
  </reference>
  <reference>
    <citation>Rosenberg SA, Restifo NP. Adoptive cell transfer as personalized immunotherapy for human cancer. Science. 2015 Apr 3;348(6230):62-8. doi: 10.1126/science.aaa4967. Review.</citation>
    <PMID>25838374</PMID>
  </reference>
  <reference>
    <citation>Morgan RA, Dudley ME, Wunderlich JR, Hughes MS, Yang JC, Sherry RM, Royal RE, Topalian SL, Kammula US, Restifo NP, Zheng Z, Nahvi A, de Vries CR, Rogers-Freezer LJ, Mavroukakis SA, Rosenberg SA. Cancer regression in patients after transfer of genetically engineered lymphocytes. Science. 2006 Oct 6;314(5796):126-9. Epub 2006 Aug 31.</citation>
    <PMID>16946036</PMID>
  </reference>
  <reference>
    <citation>Robbins PF, Morgan RA, Feldman SA, Yang JC, Sherry RM, Dudley ME, Wunderlich JR, Nahvi AV, Helman LJ, Mackall CL, Kammula US, Hughes MS, Restifo NP, Raffeld M, Lee CC, Levy CL, Li YF, El-Gamil M, Schwarz SL, Laurencot C, Rosenberg SA. Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1. J Clin Oncol. 2011 Mar 1;29(7):917-24. doi: 10.1200/JCO.2010.32.2537. Epub 2011 Jan 31.</citation>
    <PMID>21282551</PMID>
  </reference>
  <reference>
    <citation>Kobayashi E, Mizukoshi E, Kishi H, Ozawa T, Hamana H, Nagai T, Nakagawa H, Jin A, Kaneko S, Muraguchi A. A new cloning and expression system yields and validates TCRs from blood lymphocytes of patients with cancer within 10 days. Nat Med. 2013 Nov;19(11):1542-6. doi: 10.1038/nm.3358. Epub 2013 Oct 13.</citation>
    <PMID>24121927</PMID>
  </reference>
  <reference>
    <citation>Khalil DN, Smith EL, Brentjens RJ, Wolchok JD. The future of cancer treatment: immunomodulation, CARs and combination immunotherapy. Nat Rev Clin Oncol. 2016 May;13(5):273-90. doi: 10.1038/nrclinonc.2016.25. Epub 2016 Mar 15. Review. Erratum in: Nat Rev Clin Oncol. 2016 Jun;13(6):394.</citation>
    <PMID>26977780</PMID>
  </reference>
  <reference>
    <citation>Kalos M, Levine BL, Porter DL, Katz S, Grupp SA, Bagg A, June CH. T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia. Sci Transl Med. 2011 Aug 10;3(95):95ra73. doi: 10.1126/scitranslmed.3002842.</citation>
    <PMID>21832238</PMID>
  </reference>
  <reference>
    <citation>Jackson HJ, Rafiq S, Brentjens RJ. Driving CAR T-cells forward. Nat Rev Clin Oncol. 2016 Jun;13(6):370-83. doi: 10.1038/nrclinonc.2016.36. Epub 2016 Mar 22. Review.</citation>
    <PMID>27000958</PMID>
  </reference>
  <reference>
    <citation>Mueller KT, Maude SL, Porter DL, Frey N, Wood P, Han X, Waldron E, Chakraborty A, Awasthi R, Levine BL, Melenhorst JJ, Grupp SA, June CH, Lacey SF. Cellular kinetics of CTL019 in relapsed/refractory B-cell acute lymphoblastic leukemia and chronic lymphocytic leukemia. Blood. 2017 Nov 23;130(21):2317-2325. doi: 10.1182/blood-2017-06-786129. Epub 2017 Sep 21.</citation>
    <PMID>28935694</PMID>
  </reference>
  <reference>
    <citation>Tran E, Turcotte S, Gros A, Robbins PF, Lu YC, Dudley ME, Wunderlich JR, Somerville RP, Hogan K, Hinrichs CS, Parkhurst MR, Yang JC, Rosenberg SA. Cancer immunotherapy based on mutation-specific CD4+ T cells in a patient with epithelial cancer. Science. 2014 May 9;344(6184):641-5. doi: 10.1126/science.1251102.</citation>
    <PMID>24812403</PMID>
  </reference>
  <reference>
    <citation>Draper LM, Kwong ML, Gros A, Stevanović S, Tran E, Kerkar S, Raffeld M, Rosenberg SA, Hinrichs CS. Targeting of HPV-16+ Epithelial Cancer Cells by TCR Gene Engineered T Cells Directed against E6. Clin Cancer Res. 2015 Oct 1;21(19):4431-9. doi: 10.1158/1078-0432.CCR-14-3341.</citation>
    <PMID>26429982</PMID>
  </reference>
  <verification_date>September 2019</verification_date>
  <study_first_submitted>April 20, 2019</study_first_submitted>
  <study_first_submitted_qc>April 20, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">April 24, 2019</study_first_posted>
  <last_update_submitted>September 10, 2019</last_update_submitted>
  <last_update_submitted_qc>September 10, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">September 12, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Sun Yat-sen University</investigator_affiliation>
    <investigator_full_name>Hai-Qiang Mai,MD,PhD</investigator_full_name>
    <investigator_title>MD,PhD</investigator_title>
  </responsible_party>
  <keyword>EBV TCR-T cells</keyword>
  <keyword>recurrent</keyword>
  <keyword>metastatic</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Nasopharyngeal Carcinoma</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

